Reactions Weekly

, Volume 1144, Issue 1, pp 4–4 | Cite as

Adjuvant therapy with rituximab appears to be effective but risky in refractory autoimmune bullous skin diseases

Clinical study
  • 8 Downloads

Keywords

Pneumonia Pulmonary Embolism Clinical Response Adjuvant Therapy Blindness 

REFERENCE

  1. 1.
    Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M.Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. British Journal of Dermatology 156: 352-356, No. 2, Feb 2007Google Scholar

Copyright information

© Adis International limited or Adis Data Information BV 2007

Personalised recommendations